Melatonin-selenium nanoparticles inhibit oxidative stress and protect against hepatic injury induced by Bacillus Calmette-Guérin/lipopolysaccharide in mice.
Melatonin-selenium nanoparticles (MT-Se), a novel complex, were synthesized by preparing selenium nanoparticles in melatonin medium. The present investigation was designed to determine the protective effects of MT-Se against Bacillus Calmette-Guérin (BCG)/lipopolysaccharide (LPS)-induced hepatic injury in mice. In BCG/LPS-induced hepatic injury model, MT-Se administered (i.g.) at doses of 5, 10, or 20 mg/kg to BCG/LPS-treated mice for 10 days, significantly reduced the increase in plasma aminotransferase, reduced the severe extent of hepatic cell damage and the immigration of inflammatory cells. The MT-Se particles also attenuated the increase in the content of thiobarbituric acid-reactive substances and enhanced the decrease in reduced activities of superoxide dismutase and glutathione peroxidase (GPx). However, treatment with MT-Se suppressed the increase in nitric oxide levels both in plasma and liver tissue. Furthermore, supplementation with MT-Se at the dose of 10 mg/kg (composed of 9.9 mg/kg melatonin and 0.1 mg/kg selenium) had great capability to protect against hepatocellular damage than a similar dose of melatonin (10 mg/kg) or selenium (0.1 mg/kg) alone. This effect may relate to its higher antioxidant efficacy in decreasing lipid peroxidation and increasing GPx activity. These results suggest that the mode of MT-Se hepatic protective action is, at least in part, related to its antioxidant properties.
Wang
Hua
H
Institute of Clinical Pharmacology, Anhui Medical University, Hefei, Anhui Province, China.
Wei
Wei
W
Zhang
Sheng-Yi
SY
Shen
Yu-Xian
YX
Yue
Li
L
Wang
Ni-Ping
NP
Xu
Shu-Yun
SY
D000818:Animals; D006520:Hepatitis, Animal / Q000378:metabolism / Q000382:microbiology* / Q000473:pathology / Q000517:prevention & control*; D015227:Lipid Peroxidation / Q000502:physiology; D008070:Lipopolysaccharides / Q000633:toxicity*; D008297:Male; D008550:Melatonin / Q000494:pharmacology*; D051379:Mice; D009163:Mycobacterium bovis / Q000472:pathogenicity / Q000502:physiology*; D049329:Nanostructures; D009569:Nitric Oxide / Q000378:metabolism; D018384:Oxidative Stress / Q000187:drug effects*; D012643:Selenium / Q000494:pharmacology*; D014376:Tuberculosis / Q000188:drug therapy* / Q000662:veterinary
D008070:Lipopolysaccharides; D009569:Nitric Oxide; D012643:Selenium; D008550:Melatonin